|Bid||262.00 x 900|
|Ask||261.50 x 900|
|Day's Range||259.82 - 263.80|
|52 Week Range||143.13 - 275.87|
|Beta (5Y Monthly)||0.24|
|PE Ratio (TTM)||39.12|
|Forward Dividend & Yield||3.40 (1.57%)|
|Ex-Dividend Date||May 13, 2021|
|1y Target Est||N/A|
(Bloomberg) -- Biogen Inc. tumbled on Friday as setbacks for its Alzheimer’s disease drug Aduhelm helped erase all the gains the stock had made in 2021.Most Read from BloombergBillionaire Family Feud Puts a Century-Old Business Empire in JeopardyAn Arab City’s Booming Art Scene Is Also a Grab at Soft PowerThe 24-Year-Old Aiming to Dethrone Victoria’s SecretThe Winners and Losers From a Year of Ranking Covid ResilienceThe biotech stock has plunged more than 40% after reaching a six-year high in J
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The need for life-saving drugs won't subside anytime soon -- and that's what Pfizer and Eli Lilly provide.